Herbal-drug interaction induced rhabdomyolysis in a liposarcoma patient receiving trabectedin

BMC Complementary and Alternative Medicine

Volumn 13, Issue , 2013, Pages

  Strippoli, Sabino ^a   Lorusso, Vito ^a   Albano, Anna ^a   Guida, Michele ^a  

^a NATIONAL CANCER INSTITUTE GIOVANNI PAOLO II   (Italy)

Author keywords

Chokeberry (Aronia melanocarpa) drugs interaction; Drug drug interactions; Liposarcomas; Trabectedin related rhabdomyolysis

Indexed keywords

ALANINE AMINOTRANSFERASE; ARONIA MELANOCARPA EXTRACT; ASPARTATE AMINOTRANSFERASE; CREATINE KINASE; LACTATE DEHYDROGENASE; MYOGLOBIN; PLANT EXTRACT; TRABECTEDIN; UNCLASSIFIED DRUG;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARONIA MELANOCARPA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BLOOD TRANSFUSION; CANCER CHEMOTHERAPY; CASE REPORT; COMORBIDITY; COMPUTER ASSISTED TOMOGRAPHY; HERB DRUG INTERACTION; HOSPITALIZATION; HUMAN; LACTATE DEHYDROGENASE BLOOD LEVEL; LIPOSARCOMA; MALE; MEDICINAL PLANT; MOBILIZATION; MUSCLE STRENGTH; MYALGIA; PROTEIN BLOOD LEVEL; RHABDOMYOLYSIS; WALKING DIFFICULTY;

DIOXOLES; HERB-DRUG INTERACTIONS; HUMANS; LIPOSARCOMA; MALE; MIDDLE AGED; PHOTINIA; PLANT EXTRACTS; RHABDOMYOLYSIS; TETRAHYDROISOQUINOLINES;

EID: 84880956615     PISSN: None     EISSN: 14726882     Source Type: Journal    
DOI: 10.1186/1472-6882-13-199     Document Type: Article

References (26)

1. Clark MA, Fisher C, Judson I, Thomas JM. Soft-tissue sarcomas in adults. N Engl J Med 2005, 353(7):701-711. 10.1056/NEJMra041866, 16107623.
2. Demetri GD, Chawla SP, von Mehren M, Ritch P, Baker LH, Blay JY, Hande KR, Keohan ML, Samuels BL, Schuetze S, Lebedinsky C, Elsayed YA, Izquierdo MA, Gómez J, Park YC, Le Cesne A. Efficacy and safety of trabectedin in patients with advanced or metastatic liposarcoma or leiomyosarcoma after failure of prior anthracyclines and ifosfamide: results of a randomized phase II study of two different schedules. J Clin Oncol 2009, 27(25):4188-4196. 10.1200/JCO.2008.21.0088, 19652065.
3. Grosso F, D'Incalci M, Cartoafa M, Nieto A, Fernandez-Teruel C, Alfaro V, Lardelli P, Roy E, Gomez J, Kahatt C, Soto-Matos A, Judson I. A comprehensive safety analysis confirms rhabdomyolysis as an uncommon adverse reaction in patients treated with trabectedin. Cancer Chemother Pharmacol 2012, 69:1557-1565. 10.1007/s00280-012-1864-4, 3362698, 22484722.
4. Tanas MR, Goldblum JR. Fluorescence in situ hybridization in the diagnosis of soft tissue neoplasms: a review. Adv Anat Pathol 2009, 16(6):383-391. 10.1097/PAP.0b013e3181bb6b86, 19851129.
5. Stoyianni A, Kapodistrias N, Kampletsas E, Pentheroudakis G, Pavlidis N. Trabectedin-related rhabdomyolysis: an uncommon but fatal toxicity. Tumori 2011, 97:252-255.
6. Grosso F, D'Incalci M. Problems in dealing with very rare adverse effects of new anticancer drugs: the example of trabectedin. Tumori 2011, 97:256-257.
7. Brandon EF, Sparidans RW, Guijt KJ, Lowenthal S, Meijerman I, Beijnen JH, Schellens JH. In vitro characterization of the human biotransformation and CYP reaction phenotype of ET-743 (Yondelis, Trabectedin), a novel marine anti-cancer drug. Invest New Drugs 2006, 24:3-14. 10.1007/s10637-005-4538-9, 16379042.
8. Riechelmann RP, Tannock IF, Wang L, Saad ED, Taback NA, Krzyzanowska MK. Potential drug interactions and duplicate prescriptions among cancer patients. J Natl Cancer Inst 2007, 99:592-600. 10.1093/jnci/djk130, 17440160.
9. Milazzo S, Lejeune S, Ernst E. Laetrile for cancer: a systematic review of the clinical evidence. Support Care Cancer 2007, 15:583-595. 10.1007/s00520-006-0168-9, 17106659.
10. Engdal S, Klepp MO, Nilsen OG. Identification and exploration of herb-drug combinations used by cancer patients. Integr Cancer Ther 2009, 8:29-36. 10.1177/1534735408330202, 19174505.
11. Shi S, Klotz U. Drug interactions with herbal medicines. Clin Pharmacokinet 2012, 51(2):77-104. 10.2165/11597910-000000000-00000, 22257149.
12. Yang CY, Chao PD, Hou YC, Tsai SY, Wen KC, Hsiu SL. Marked decrease of cyclosporin bioavailability caused by coadministration of ginkgo and onion in rats. Food Chem Toxicol 2006, 44(9):1572-1578. 10.1016/j.fct.2006.04.008, 16762474.
13. Tang JC, Yang H, Song XY, Song XH, Yan SL, Shao JQ, Zhang TL, Zhang JN. Inhibition of cytochrome P450 enzymes by rhein in rat liver microsomes. Phytother Res 2009, 23(2):159-164. 10.1002/ptr.2572, 18814214.
14. Chow HH, Hakim IA, Vining DR, Crowell JA, Cordova CA, Chew WM, Xu MJ, Hsu CH, Ranger-Moore J, Alberts DS. Effects of repeated green tea catechin administration on human cytochrome P450 activity. Cancer Epidemiol Biomarkers Prev 2006, 15(12):2473-2476. 10.1158/1055-9965.EPI-06-0365, 17164372.
15. Obach RS. Inhibition of human cytochrome P450 enzymes by constituents of St. John's Wort, an herbal preparation used in the treatment of depression. J Pharmacol Exp Ther 2000, 294(1):88-95.
16. Anderson GD, Rosito G, Mohustsy MA, Elmer GW. Drug interaction potential of soy extract and Panax ginseng. J Clin Pharmacol 2003, 43(6):643-648.
17. Hansen TS, Nilsen OG. In vitro CYP3A4 metabolism: inhibition by Echinacea purpurea and choice of substrate for the evaluation of herbal inhibition. Basic Clin Pharmacol Toxicol 2008, 103(5):445-449. 10.1111/j.1742-7843.2008.00307.x, 18947363.
18. Greenblatt DJ, Leigh-Pemberton RA, von Moltke LL. In vitro interactions of water-soluble garlic components with human cytochromes p450. J Nutr 2006, 136:806S-809S.
19. Kulling SE, Rawel HM. Chokeberry (Aronia melanocarpa) - a review on the characteristic components and potential health effects. Planta Med 2008, 74:1625-1634. 10.1055/s-0028-1088306, 18937167.
20. Choi JS, Piao YJ, Kang KW. Effects of quercetin on the bioavailability of doxorubicin in rats: role of CYP3A4 and P-gp inhibition by quercetin. Arch Pharm Res 2011, 34(4):607-613. 10.1007/s12272-011-0411-x, 21544726.
21. Lala G, Malik M, Zhao CW, He J, Kwon Y, Giusti MM. Anthocyaninrich extracts inhibit multiple biomarkers of colon cancer in rats. Nutr Cancer 2006, 54:84-93. 10.1207/s15327914nc5401_10, 16800776.
22. Olas B, Wachowicz B, Tomczak A, Erler J, Stochmal A, Oleszek W. Comparative anti-platelet and antioxidant properties of polyphenol-rich extracts from: berries of Aronia melanocarpa, seeds of grape and bark of Yucca schidigera in vitro. Platelets 2008, 19(1):70-77. 10.1080/09537100701708506, 18231940.
23. Szaefer H, Krajka-Kuźniak V, Ignatowicz E, Adamska T, Baer-Dubowska W. Chokeberry (Aronia melanocarpa) juice modulates 7,12-dimethylbenz[a]anthracene induced hepatic but not mammary gland phase I and II enzymes in female rats. Environ Toxicol Pharmacol 2011, 31(2):339-346. 10.1016/j.etap.2010.12.006, 21787703.
24. Tatro DS. Drug interaction facts 2009, St. Louis: Facts and Comparisons.
25. Lamm W, Amann G, Brodowicz T. Case report of suspected Rhabdomyolysis during treatment with Trabectedin in a patient with Metastatic Leiomyosarcoma. Case Rep Oncol 2010, 3:477-479. 10.1159/000323261, 3100270, 21611101.
26. Yap KY, Kuo EY, Lee JJ, Chui WK, Chan A. An onco-informatics database for anticancer drug interactions with complementary and alternative medicines used in cancer treatment and supportive care: an overview of the OncoRx project. Support Care Cancer 2009, 10:1011-1019.